98 related articles for article (PubMed ID: 20109952)
1. Maintenance therapy for non-small-cell lung cancer.
Belani CP; Liao J
Lancet; 2010 Jan; 375(9711):281-2. PubMed ID: 20109952
[No Abstract] [Full Text] [Related]
2. Maintenance therapy in non-small-cell lung cancer.
Stinchcombe TE; West HL
Lancet; 2009 Oct; 374(9699):1398-400. PubMed ID: 19767096
[No Abstract] [Full Text] [Related]
3. Palliative chemotherapy: do we need yet another end-point?
van Meerbeeck JP; Baas P
Eur J Cancer; 2009 Sep; 45(13):2234-5. PubMed ID: 19524432
[No Abstract] [Full Text] [Related]
4. Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.
Okamoto I; Takeda K; Daga H; Miyazaki M; Yonesaka K; Kiyota H; Tsurutani J; Ueda S; Ichikawa Y; Takeda M; Sekiguchi R; Tominaga K; Enatsu S; Nambu Y; Nakagawa K
Lung Cancer; 2010 Nov; 70(2):168-73. PubMed ID: 20236726
[TBL] [Abstract][Full Text] [Related]
5. A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer.
Chouaid C; Nathan F; Pemberton K; Morris T
Cancer Chemother Pharmacol; 2011 May; 67(5):1203-8. PubMed ID: 21153822
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies.
Surmont V; Smit EF; de Jonge M; Aerts JG; Nackaerts K; Vernhout R; Gras J; Van Wijk A; Phernambucq EC; van Meerbeeck JP; Senan S; Kraaij CJ; Chouaki N; Praag J; van Klaveren RJ
Lung Cancer; 2010 Sep; 69(3):302-6. PubMed ID: 20096951
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed plus bevacizumab for second-line therapy of non-small-cell lung cancer: the importance of patient selection.
Araujo AM
J Clin Oncol; 2010 Mar; 28(8):e131; author reply e132. PubMed ID: 20100954
[No Abstract] [Full Text] [Related]
9. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
Buikhuisen WA; Burgers JA; Vincent AD; Schellens JH; Beijnen JH; Smit EF; Joerger M
J Clin Oncol; 2010 Sep; 28(27):e482-3; author reply e484. PubMed ID: 20606096
[No Abstract] [Full Text] [Related]
10. Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question.
Galetta D; Rossi A; Pisconti S; Millaku A; Colucci G
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S30-3. PubMed ID: 21129607
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer.
Bogart JA; Govindan R
Clin Lung Cancer; 2006 Jan; 7(4):285-7. PubMed ID: 16512986
[No Abstract] [Full Text] [Related]
12. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
Bennouna J; Havel L; Krzakowski M; Kollmeier J; Gervais R; Dansin E; Serke M; Favaretto A; Szczesna A; Cobo M; Ciuffreda L; Jassem J; Nicolini M; Ramlau R; Amoroso D; Melotti B; Almodovar T; Riggi M; Caux NR; Vaissière N; Tan EH
Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
[TBL] [Abstract][Full Text] [Related]
13. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer.
Kim HS; Lee GW; Kim JH; Kim HY; Kwon JH; Song HH; Kim HJ; Jung JY; Jang G; Choi DR; Park SM; Shin TR; Lee HS; Zang DY
Lung Cancer; 2010 Oct; 70(1):71-6. PubMed ID: 20096475
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of pemetrexed continuation--maintenance after carboplatin-based induction in untreated non-squamous non-small cell lung cancer.
Minami S; Kijima T; Komuta K; Kumagai T; Imamura F; Yokota S; Takeuchi Y; Nakatani T; Tachibana I; Kawase I
Anticancer Res; 2013 Dec; 33(12):5535-42. PubMed ID: 24324094
[TBL] [Abstract][Full Text] [Related]
18. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
Galetta D; Pisconti S; Cinieri S; Pappagallo GL; Gebbia V; Borsellino N; Maiello E; Rinaldi A; Montrone M; Rizzo P; Marzano N; Sasso N; Febbraro A; Colucci G
Clin Lung Cancer; 2011 Nov; 12(6):402-6. PubMed ID: 21831718
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]